GlassScriptPhysician profile
Aamir Iqbal
NPI 1174054019
$3,421.66
in general payments reported to CMS, 2019-2025
27 companies · $924 in 2025
The $924 reported for 2025 was more than what 94% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $219 · 2021: $713 · 2022: $411 · 2023: $426 · 2024: $728 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,047 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,046.65 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $901.46 | 2020-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $303.13 | 2022-2025 | |
| Abbvie INC. | $231.95 | 2021-2025 | |
| Novo Nordisk INC | $231.57 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $225.48 | 2024-2025 | Airsupra, Breztri |
| Amarin Pharma, INC. | $212.95 | 2020-2021 | |
| Ethicon US, LLC | $202.25 | 2024 | Stratafix |
| Lilly USA, LLC | $169.77 | 2021-2025 | Mounjaro, Kisunla, Zepbound |
| Eisai INC. | $132.64 | 2020-2025 | |
| Esperion Therapeutics, INC. | $124.33 | 2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.64 | 2022-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $64.87 | 2023-2024 | Rexulti |
| Mallinckrodt Hospital Products INC. | $55.69 | 2023-2024 | Acthar |
| Stryker Corporation | $50.68 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.32 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $45.83 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Depuy Synthes Sales INC. | $42.57 | 2022 | |
| Pfizer INC. | $42.13 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $39.95 | 2022-2023 | Quviviq |
| Abbott Laboratories | $39.80 | 2022 | |
| Mylan Specialty L.P. | $33.04 | 2023 | Yupelri |
| Astellas Pharma US INC | $32.77 | 2024 | Veozah |
| Shield Therapeutics INC | $30.86 | 2023 | Accrufer |
| Genzyme Corporation | $29.11 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.42 | 2025 | |
| Ibsa Pharma INC. | $24.22 | 2024 | Licart, Flector, Tirosint |
| Exact Sciences Corporation | $14.23 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aamir Iqbal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.